K

Kiniksa Pharmaceuticals Ltd
D

KNSA

79.380
USD
0.87
(1.11%)
قبل الجلسة·78.010USD-1.370(-1.73%)
حجم التداول
8,053
الربح لكل سهم
1
العائد الربحي
-
P/E
80
حجم السوق
6,193,546,152
أصول ذات صلة المقالات
المزيد

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: الرعاية الصحية
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.